Last reviewed · How we verify

NCT04860908

COVID 19 ANTOBODIES IN PREGNANT WOMEN AND THEIR CONNECTION TO BETA CELL FUNCTION IN THE FETUS

Status unknown Last updated 27 April 2021
What this trial tests

trial testing no intervention, observation only in Generation of Anti COVID-19 Antibodies in a Fetus, Whose Mother Was Exposed to COVID or Was Vaccinated During Pregnancy in 100 participants. Status unknown.

Timeline
26 April 2021
Primary endpoint
1 January 2022
1 July 2022

Quick facts

Lead sponsorMaaynei Hayesha Medical Center
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment100
Start date26 April 2021
Primary completion1 January 2022
Estimated completion1 July 2022
Sites1 location across Israel

Drugs / interventions tested

Conditions studied

Sponsor

Maaynei Hayesha Medical Center

Who can join

Adults 18 to 48, female only, with Generation of Anti COVID-19 Antibodies in a Fetus, Whose Mother Was Exposed to COVID or Was Vaccinated During Pregnancy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to check for the presence of COVID 19 antibodies \[Covid-19, GAD-65, IA-2, ICA\] in the blood of laboring women who have been exposed to either the virus itself or to the vaccine during pregnancy . The same test will be done on cord blood. Then the types of antibodies will be compared, between maternal and neonatal blood. The blood will be taken along with routine blood tests without additional punctures of Mother or Baby.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04860908.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing